Storia in 8 fonti

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

DT120, a psychedelic that activates serotonin receptors, was generally well tolerated, with mostly mild side effects occurring on dosing day and no serious safety concerns.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

gizmodo.com1 mese fa

LSD Just Passed Its Biggest Test Yet for Treating Depression

Definium Therapeutics annuncia Phase III di DT120 (LSD proprietaria): singola dose raggiunge 35% remissione versus 7% placebo nella depressione clinica. Per manager tech il segnale è una terapia single-dose disruptive rispetto ai trattamenti cronici attuali, con impatto potenziale su employee wellness e healthcare spending aziendale.

Leggi questa versione → originale

Timeline cronologica

lunedì 22 giugno 2026·zerohedge.com
Psychedelic Stocks Could Explode Higher
Positive clinical data is starting to trickle in and Trump wants to fast-track the sector...
lunedì 22 giugno 2026·statnews.com
Definium LSD therapy helped patients with major depression in late-stage trial
Definium Therapeutics said that its LSD therapy helped patients with major depression in its first Phase 3 trial, bringing the psychedelic drug closer to a potential approval.

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

Confronto fonti

LSD Just Passed Its Biggest Test Yet for Treating Depression

Timeline cronologica

Psychedelic Stocks Could Explode Higher

Definium LSD therapy helped patients with major depression in late-stage trial

Definium reports Phase 3 hit for LSD drug in severe form of depression

Biotech Goes Sky-High After LSD Drug Treats Depression

Definium LSD therapy helped patients with major depression in late-stage trial

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Psychedelic Stocks Could Explode Higher

Definium reports Phase 3 hit for LSD drug in severe form of depression

Definium Shares Soar After Reporting Positive Phase 3 Results For Single-Dose Depression Treatment - Defi

Biotech Goes Sky-High After LSD Drug Treats Depression

Definium Soars As Much As 50% After LSD-Based Depression Drug Meets Late-Stage Clinical Trial Goal

Definium Therapeutics, Inc. Announces Proposed Public Offering

LSD Just Passed Its Biggest Test Yet for Treating Depression

What's Going On With Definium Therapeutics Stock Tuesday? - Definium Therapeutics (NASDAQ:DFTX)

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

LSD's Depression Win; Summer Heat and Suicide; Antipsychotic Nonresponse Predictors